ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Non-GAAP net income: $7,493M in Q2 2026, up 31.9% from a year earlier.
Latest, Q2 2026
7,493
Period ended Jun 30, 2026
Change on a year earlier
+31.9%
5,679 in Q2 2025
History
37 quarters
Since Q4 2016
Sources
30
Documents cited below
Where the Q2 2026 figure comes from
“|| Net income - Non-GAAP | $ | 7,493 | $ | 5,680 | $ | 15,156 | $ | 8,684”
Source: Earnings Release (Form 8-K FY2026Q2 EX-99.1) (filed 2026-08-05) ↗
Reported in Form 8-K Earnings Releases (Non-GAAP Reconciliation Schedules).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up non-GAAP net income
Cite this data
StockData. (2026). Eli Lilly Non-GAAP net income ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ni-nongaap
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.